Alzheimer’s Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2024-2030
The Alzheimer’s Therapeutics Market size was estimated at USD 6.14 billion in 2023 and expected to reach USD 6.66 billion in 2024, at a CAGR 8.63% to reach USD 10.96 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer’s Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer’s Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Alzheimer’s Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.
Market Segmentation & Coverage
This research report categorizes the Alzheimer’s Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Cholinesterase Inhibitors
Medication
Cholinesterase inhibitors
Online Pharmacies
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Alzheimer’s Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer’s Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Alzheimer’s Therapeutics Market?
- What is the market share of the leading vendors in the Alzheimer’s Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Alzheimer’s Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Alzheimer’s Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidences of Alzheimer’s among population
- 5.1.1.2. Growing development and availability of pipeline drugs
- 5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer’s
- 5.1.2. Restraints
- 5.1.2.1. Capital intensive treatment for Alzheimer’s
- 5.1.3. Opportunities
- 5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
- 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
- 5.1.4. Challenges
- 5.1.4.1. Stringent drug approval processes
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Alzheimer’s Therapeutics Market, by Drug Class
- 6.1. Introduction
- 6.2. Cholinesterase Inhibitors
- 6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist
- 7. Alzheimer’s Therapeutics Market, by Type
- 7.1. Introduction
- 7.2. Medication
- 7.3.1. Cholinesterase inhibitors
- 7.3.2. Donepezil
- 7.3.3. Galantamine
- 7.3.4. Rivastigmine
- 7.3. NMDA Receptor Antagonist
- 8. Alzheimer’s Therapeutics Market, by Distribution
- 8.1. Introduction
- 8.2. Online Pharmacies
- 8.3. Retail Pharmacies
- 9. Americas Alzheimer’s Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Alzheimer’s Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Alzheimer’s Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. New Product Launch & Enhancement
- 12.3.1.1. The Next Phase of Alzheimer’s Therapeutics with Alzstatin ACD680
- 12.3.1.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer’s
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. AbbVie Inc.
- 13.1.2. AC Immune SA
- 13.1.3. Acadia Pharmaceuticals Inc.
- 13.1.4. Alnylam Pharmaceuticals, Inc.
- 13.1.5. AlzeCure Pharma AB
- 13.1.6. Alzheon, Inc.
- 13.1.7. AstraZeneca PLC
- 13.1.8. Biogen Inc.
- 13.1.9. Cassava Sciences, Inc.
- 13.1.10. Cognition Therapeutics, Inc.
- 13.1.11. Corium, Inc.
- 13.1.12. Eisai Co., Ltd.
- 13.1.13. Eli Lilly and Company
- 13.1.14. F. Hoffmann-La Roche Ltd.
- 13.1.15. Grifols S.A.
- 13.1.16. H. Lundbeck A/S
- 13.1.17. Luye Pharma Group Ltd.
- 13.1.18. Merz Pharma GmbH & Co. KGaA
- 13.1.19. NeuroVision Imaging, Inc.
- 13.1.20. Novartis AG
- 13.1.21. Oryzon Genomics, S.A.
- 13.1.22. Pfizer, Inc.
- 13.1.23. Siemens Healthcare GmbH
- 13.1.24. Synaptogenix, Inc.
- 13.1.25. TauRx Pharmaceuticals Ltd.
- 13.1.26. VTV Therapeutics
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ALZHEIMER’S THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ALZHEIMER’S THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 10. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
- FIGURE 12. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ALZHEIMER’S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook